NUVL
Nuvalent IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$9.75B
P/E Ratio
—
EPS
$-6.06
Beta
1.15
52W High
$123.62
52W Low
$71.13
50-Day MA
$103.74
200-Day MA
$98.49
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nuvalent Inc
Nuvalent Inc. is an innovative clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to provide cutting-edge treatment solutions that specifically target genetic mutations driving tumor growth, ultimately enhancing patient outcomes and minimizing adverse effects. With a strong pipeline of highly selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating a steadfast commitment to revolutionizing cancer treatment and improving patient care across the oncology sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -41.20% |
| Return on Assets | -22.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $14.89 |
| Price-to-Book | 8.32 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -22.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.69M |
| Float | $49.00M |
| % Insiders | 2.76% |
| % Institutions | 113.07% |
Historical Volatility
HV 10-Day
199.40%
HV 20-Day
138.66%
HV 30-Day
113.96%
HV 60-Day
83.11%
HV Rank
99.2%
Volatility is currently expanding
Analyst Ratings
Consensus ($128.12 target)
4
Strong Buy16
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026